Sonesitatug Vedotin + Capecitabine for Stomach Cancer

This trial explores the effectiveness and safety of a new treatment combination for certain types of advanced stomach cancer. Researchers are testing how well sonesitatug vedotin (an experimental treatment) works with capecitabine, sometimes adding other drugs like rilvegostomig or nivolumab. The study targets individuals with advanced gastric, gastroesophageal, or esophageal cancer that hasn't been treated before and who have a specific protein (CLDN18.2) present in their cancer. Participants should not have a history of HER2-positive cancer and must meet other health criteria. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research shows that the combination of sonesitatug vedotin and capecitabine is generally well-tolerated by patients with advanced stomach cancer. Previous studies found that this treatment can be administered safely, with most side effects being manageable. Some patients experienced common side effects like nausea and tiredness, but serious side effects were rare.

For the combination of sonesitatug vedotin with nivolumab and capecitabine, studies indicate that this mix is also well-tolerated. Common side effects include tiredness and mild skin reactions. These side effects are typical with cancer treatments and are closely monitored by doctors.

In the group receiving sonesitatug vedotin, rilvegostomig, and capecitabine, research suggests this treatment is generally safe. Few serious side effects have been reported, with most issues being mild, such as tiredness and mild digestive problems.

Researchers are excited about these treatments for stomach cancer because they introduce unique combinations and mechanisms. Sonesitatug Vedotin is an antibody-drug conjugate, which means it delivers chemotherapy directly to cancer cells, potentially reducing side effects and improving effectiveness compared to traditional chemotherapy. The combination of Sonesitatug Vedotin with Capecitabine, and additional drugs like Rilvegostomig and Nivolumab in some arms, offers a multifaceted approach that targets cancer cells more precisely. This approach could provide a significant advantage over standard treatments like CAPOX or FOLFOX, which are broader in scope. By harnessing targeted therapy, these treatments may offer better outcomes and fewer side effects for patients.

Research has shown that the drug sonesitatug vedotin, when combined with capecitabine, may help treat stomach cancer. In a study with 109 patients, about 29% experienced tumor shrinkage. Participants in Arm D of the trial will receive the combination of sonesitatug vedotin and capecitabine.